A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)

Summary

Prevalence of metabolic syndrome in korea is increasing. There is no clinical trial targeting on such increasing populations like metabolic syndrome patients with Vytorin® in korea. Therefore this trial will help evaluate the lipid lowering effect of Vytorin® in asian population with metabolic syndrome.

Timeline

Start

2007-07

Primary completion

2008-08

Completion

2008-08

Outcome

Met primary endpoint

registry analysis (unspecified test); Vytorin vs Atorvastatin; p <0.0001; ANCOVA NCT00496730 ↗

Drugs

Indications